This article was distributed by the Associated Press.
Reports of issues with weight loss drugs containing semaglutide, the active ingredient in Ozempic, or tirzepatide, the active ingredient in Mounjaro, have seen a sharp rise since 2019
Some common side effects, such as nausea, vomiting, and diarrhea, were reported in higher numbers in the group taking a 1 mg dose compared to those on a lower dose
We are committed to addressing the growing obesity epidemic in the United States by empowering individuals with safe, effective, and medically supervised solutions
The absence of salt content in semaglutide, or ensuring that semaglutide is free from salts, is important for a few reasons related to its stability, efficacy, and how the body absorbs and reacts to the drug: These factors combined ensure that compounded semaglutide remains a highly effective and safer treatment option Semaglutide compounded with salts